AbCellera Biologics
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems ...
Latest News
9 hours ago · marketbeat.com
AbCellera Biologics Targets 2027 Late-Stage Trial for Hot Flash TreatmentAbCellera Biologics NASDAQ: ABCL is preparing to advance its experimental hot flash treatment ABCL635 into late-stage studies, with a registrational trial potentially starting around the middle of 2027, Chief Executive Carl Hansen said at the Jefferies 2026 Global Healthcare Conference in London.
3 days ago · seekingalpha.com
AbCellera Biologics Inc. (ABCL) Presents at Stifel 2026 Healthcare Conference 2026 TranscriptAbCellera Biologics Inc. ( ABCL ) Stifel 2026 Healthcare Conference 2026 November 10, 2026 7:00 PM EST Company Participants Carl L. Hansen - CEO, President & Chairperson Conference Call Participants Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Stephen Willey Stifel, Nicolaus & Company, Incorporated, Research Division All right.
4 days ago · zacks.com
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?Here is how AbCellera Biologics Inc. (ABCL) and Editas Medicine (EDIT) have performed compared to their sector so far this year.
4 days ago · marketbeat.com
AbCellera Biologics Eyes Phase 3 for Hot-Flash Drug After Promising Midstage ResultsAbCellera Biologics NASDAQ: ABCL is preparing to advance its experimental hot-flash treatment ABCL635 into late-stage development next year after a midstage study produced stronger-than-expected efficacy results, CEO Carl Hansen said at a Stifel event.
7 days ago · seekingalpha.com
AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call TranscriptAbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call Transcript
7 days ago · marketbeat.com
What AbCellera Biologics (ABCL) Said on Its Q3 Earnings CallAbCellera Biologics NASDAQ: ABCL plans to advance its experimental hot flash treatment ABCL635 into late-stage development in 2027 after reporting positive mid-stage results, while shelving further development of a separate antibody candidate for now.
7 days ago · zacks.com
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue EstimatesAbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.19 per share a year ago.
1 month ago · businesswire.com
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual MeetingVANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting.
2 months ago · businesswire.com
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026.
2 months ago · zacks.com
ABCL Stock Surges 121% in 3 Months: Here's What You Need to KnowAbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ABCL